Scholarlink

Background <p>This study was motivated by the high prevalence of anemia of inflammation (AI) in systemic lupus erythematosus (SLE) and the poorly explored potential link between the underlying inflammatory drive and hepatic complications. The IL-6/hepcidin axis is a key pathway in AI, but its role in concurrent liver pathology is not well defined. The aim of this study was to investigate the relationship between the IL-6/hepcidin axis, AI, and hepatic fibrosis in Egyptian SLE patients.</p> Methods <p>102 SLE patients and 25 healthy controls were enrolled in the study. Serum levels of IL-6, hepcidin, IL-33, liver enzymes (AST, ALT) as markers of hepatocellular injury, and other clinical parameters were measured by Enzyme-Linked Immunosorbent Assay (ELISA). Disease activity was assessed using Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and liver fibrosis was evaluated non-invasively using the AST to Platelet Ratio Index (APRI).</p> Results <p>Patients were classified into those with and without AI. AI was present in 91.2% of patients. The SLE cohort showed significantly elevated IL-6, hepcidin, and liver enzymes compared to controls. APRI-defined hepatic fibrosis (including cirrhosis) was detected in 30 patients (29.41%), all within the AI subgroup. Strong positive correlations were found between hepcidin levels and SLEDAI (<i>r</i> = 0.46; <i>p</i> &lt; 0.001), AST (<i>r</i> = 0.777; <i>p</i> &lt; 0.001), and ALT (<i>r</i> = 0.747; <i>p</i> &lt; 0.001). However, neither hepcidin (AUC = 0.566, 95% CI: 0.449–0.683, <i>p</i> = 0.267) nor IL-6 (AUC = 0.541, 95% CI: 0.416–0.665, <i>p</i> = 0.516) demonstrated clinically useful diagnostic accuracy for detecting APRI-defined liver fibrosis.</p> Conclusions <p>Chronic IL-6-driven inflammation in SLE propels a dual pathology; inducing hepcidin-mediated AI and being associated with liver damage. Hepcidin and IL-6 are correlates rather than causes of fibrosis. APRI remains a reliable non-invasive tool for identifying patients at risk of hepatic fibrosis in SLE, particularly those with AI, and should be incorporated into routine clinical assessment.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Dysregulation of the IL-6/hepcidin axis in Egyptian systemic lupus erythematosus patients: associations with anemia of inflammation and liver fibrosis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月29日

查看全文
  • Mennatallah Saied,
  • Mary Wadie,
  • Salwa Fouad,
  • Alyaa Farid,
  • Mohamed Nasser

摘要

Background

This study was motivated by the high prevalence of anemia of inflammation (AI) in systemic lupus erythematosus (SLE) and the poorly explored potential link between the underlying inflammatory drive and hepatic complications. The IL-6/hepcidin axis is a key pathway in AI, but its role in concurrent liver pathology is not well defined. The aim of this study was to investigate the relationship between the IL-6/hepcidin axis, AI, and hepatic fibrosis in Egyptian SLE patients.

Methods

102 SLE patients and 25 healthy controls were enrolled in the study. Serum levels of IL-6, hepcidin, IL-33, liver enzymes (AST, ALT) as markers of hepatocellular injury, and other clinical parameters were measured by Enzyme-Linked Immunosorbent Assay (ELISA). Disease activity was assessed using Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and liver fibrosis was evaluated non-invasively using the AST to Platelet Ratio Index (APRI).

Results

Patients were classified into those with and without AI. AI was present in 91.2% of patients. The SLE cohort showed significantly elevated IL-6, hepcidin, and liver enzymes compared to controls. APRI-defined hepatic fibrosis (including cirrhosis) was detected in 30 patients (29.41%), all within the AI subgroup. Strong positive correlations were found between hepcidin levels and SLEDAI (r = 0.46; p < 0.001), AST (r = 0.777; p < 0.001), and ALT (r = 0.747; p < 0.001). However, neither hepcidin (AUC = 0.566, 95% CI: 0.449–0.683, p = 0.267) nor IL-6 (AUC = 0.541, 95% CI: 0.416–0.665, p = 0.516) demonstrated clinically useful diagnostic accuracy for detecting APRI-defined liver fibrosis.

Conclusions

Chronic IL-6-driven inflammation in SLE propels a dual pathology; inducing hepcidin-mediated AI and being associated with liver damage. Hepcidin and IL-6 are correlates rather than causes of fibrosis. APRI remains a reliable non-invasive tool for identifying patients at risk of hepatic fibrosis in SLE, particularly those with AI, and should be incorporated into routine clinical assessment.

Graphical Abstract